Brief: Clovis Oncology And Evergreen Theragnostics Initiate Agreement For Actinium-225-Labeled FAP-2286
16/03/2022 12:38
March 16 (Reuters) - Clovis Oncology Inc CLVS.O :
* CLOVIS ONCOLOGY AND EVERGREEN THERAGNOSTICS INITIATE
DEVELOPMENT
AND MANUFACTURING SERVICES AGREEMENT FOR ACTINIUM-225-LABELED
FAP-2286
* CLOVIS ONCOLOGY INC - EVERGREEN WILL DEVELOP
(225)AC-FAP-2286 AT
ITS FACILITY IN SPRINGFIELD
* CLOVIS ONCOLOGY INC - UNDER TERMS OF AGREEMENT, EVERGREEN
WILL
DEVELOP (225)AC-FAP-2286 AT ITS FACILITY IN SPRINGFIELD, N.J.
Source text for Eikon: ID:nBw3z7lh9a
Further company coverage: CLVS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clovis Oncology
See all newsBrief: Clovis Oncology Inc - On April 5, 2023, Entered Into Asset Purchase Agreement With Pharma& To Sell Product Business For Upfront Payment Of $70 Million
Brief: Clovis Oncology Enters Into Financing Agreement
Brief: Clovis Oncology Inc Received Written Notice From Nasdaq That Company's Common Stock Will Be Delisted From Nasdaq
U.S. STOCKS ON THE MOVE-Nike, Faraday Future, PBF Energy
U.S. STOCKS ON THE MOVE-Natural gas, Box Inc, Weber